Filling the gap between Guidelines and Real World in the cardiovascular approach to the diabetic patients: the need for a call to action

Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease—A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V

(2020) Giulia Ferrannini et al.   DIABETES CARE

A revolution in diabetes care: novel drugs and new recommendations

(2020) Thomas F Lüscher   EUROPEAN HEART JOURNAL

Report from the 5th cardiovascular outcome trial (CVOT) summit

(2020) Oliver Schnell et al.   Cardiovascular Diabetology

COVID-19 and diabetes management: What should be considered?

(2020) Antonio Ceriello et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Is Coronary Artery Disease Inevitable in Type 2 Diabetes? From a Glucocentric to a Holistic View on Patient Management

(2020) Giulia Ferrannini et al.   DIABETES CARE

Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis

(2020) Malik Elharram et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes

(2020) Guntram Schernthaner et al.   Cardiovascular Diabetology

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021

(2020)   DIABETES CARE

Composite Cardiovascular Risk Factor Target Achievement and its Predictors in US Adults with Diabetes: The Diabetes Collaborative Registry

(2019) Wenjun Fan et al.   DIABETES OBESITY & METABOLISM

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

Evaluation of the Cascade of Diabetes Care in the United States, 2005-2016

(2019) Pooyan Kazemian et al.   JAMA Internal Medicine

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2019) John B. Buse et al.   DIABETOLOGIA

Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: Incidence and risk factors

(2018) Cyril Breuker et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

2018 ESC/ESH Guidelines for the management of arterial hypertension

(2018) Bryan Williams et al.   EUROPEAN HEART JOURNAL

Improving health literacy in patients with chronic conditions: A call to action

(2018) Patrick Dunn et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2018) Aidin Rawshani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data

(2016) Naveed Sattar et al.   Lancet Diabetes & Endocrinology

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

(2010) The Emerging Risk Factors Collaboration   LANCET

Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: The National Health and Nutrition Examination Survey 2003-2004

(2008) Heli Ghandehari et al.   AMERICAN HEART JOURNAL

Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis

(2008)   LANCET

Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes

(2008) Peter Gæde et al.   NEW ENGLAND JOURNAL OF MEDICINE